Analysis. This article reports what is publicly known about SR17018 as of May 2026, the consumer product being sold under that name, and the clinical context in which it is being discussed in the ibogaine field. It is not medical advice. SR17018 has not been studied in any human clinical trial. Anyone considering its use should talk to a physician.

There is a tablet you can buy online. It is strawberry-flavored. It comes in a three-pack. The active ingredient is a synthetic compound that, until recently, only existed in academic pharmacology labs and on the shelves of research-chemical suppliers, in milligram quantities, for animal studies. Now it is sold direct-to-consumer through a brand called O.R. Reset, and through head-shop retailers that also stock 7-OH kratom, MGM-15, and Delta 8.

The tablet is marketed as a 10-day "receptor reset" for people coming off 7-OH and similar high-potency kratom products. In other words: it sits on the same shelf as the thing the customer is trying to escape.

That fact alone is worth pausing on. The withdrawal cure and the withdrawal cause are on the same shelf, sold by the same retailers, sometimes by adjacent brands. We will come back to this.

What SR17018 actually is

SR17018 is a small molecule developed in the lab of Laura Bohn at the Scripps Research Institute (now the Herbert Wertheim UF Scripps Institute) in Jupiter, Florida. It belongs to a class of compounds called G-protein-biased mu-opioid receptor agonists. The short version: it binds to the same receptor that morphine, oxycodone, fentanyl, kratom, and 7-OH bind to, but it activates that receptor in a way that, in animal studies, produced analgesia without the respiratory depression that makes traditional opioids dangerous in overdose.

That is genuinely interesting science. Biased agonism has been one of the most active areas of opioid research for over a decade, and SR17018 is among the more frequently cited compounds in that work.

Here is what it is not.

It is not an FDA-approved drug. It has never been through a Phase 1 human safety trial. Every published study I have been able to find is either in vitro (cells in a dish) or in vivo in rodents. There is no human pharmacokinetic data. There is no human dosing data. There is no human side-effect profile. There is no human dependence or withdrawal data. None of that exists in the peer-reviewed literature.

It is not a controlled substance in the United States. The DEA has not scheduled it. Germany did, in late 2025, under its Neue-psychoaktive-Stoffe-Gesetz law for novel psychoactive substances. The US has not followed.

It is not a dietary supplement. SR17018 was synthesized in the 2010s. It has no history as a food or supplement ingredient and cannot qualify under the Dietary Supplement Health and Education Act of 1994. Anything labeled as a "supplement" that contains SR17018 is being labeled incorrectly.

What it is, right now, in the United States, is an unapproved new drug being sold to consumers in a regulatory window that the FDA has not yet closed. That window exists for a familiar reason: the agency has finite enforcement bandwidth, and SR17018 is not yet on its priority list. Tianeptine sat in the same window for years. Phenibut sat there. Several SARMs sat there. Each one, eventually, drew warning letters and either disappeared from US retail or moved further underground.

Why people think it could bridge 7-OH withdrawal

The pharmacological argument for SR17018 as a 7-OH bridge is not crazy.

7-hydroxymitragynine, the active alkaloid in concentrated kratom products, is a partial mu-opioid receptor agonist. People who use it daily, especially the high-dose pure 7-OH products, develop physical dependence. The withdrawal looks like opioid withdrawal: restless legs, sweating, GI distress, anxiety, insomnia, cravings. By every account from clinics that treat it, the experience is miserable.

The conventional medical bridge for opioid dependence is buprenorphine or methadone. Both are partial or full mu-opioid agonists. Both work because they occupy the receptor with a long half-life and prevent withdrawal while a patient stabilizes. Buprenorphine, in particular, is the standard of care for opioid use disorder in the United States.

The SR17018 pitch, as it appears in consumer marketing, is essentially: here is a compound that hits the same receptor with less of the dangerous downstream signaling, taken for a short window, with the goal of letting your body recalibrate.

If SR17018 had completed human trials and shown that profile in actual patients, that would be a meaningful addition to addiction medicine.

Where the idea falls apart

It hasn't. And the consumer pitch glosses over several things that matter.

First, SR17018 is still a mu-opioid agonist. Biased or not, it binds the receptor a patient is trying to get clean from. "Bridging" from 7-OH to SR17018 does not reset the receptor. It swaps one ligand for another while the underlying state of opioid dependence continues. A patient who finishes a 10-day SR17018 course and stops is at risk of withdrawal from the SR17018 itself, not just from the 7-OH they originally came off. Whether SR17018 withdrawal is mild or severe in humans, no one knows. There is no human data.

Second, the framing of "test negative on kratom before ibogaine" sometimes gets used as a reason to bridge with SR17018. That framing misunderstands what ibogaine clinics need. Clinics screen for kratom and 7-OH because the patient's actual receptor state matters for the ibogaine protocol, not because the urine screen is the goal. Testing negative on a kratom panel while still mu-opioid dependent does not make ibogaine safer. It hides the dependence from the screen.

Third, and this is the part that should give anyone pause: the manufacturer is the only quality control. There are no FDA inspections of the facility. There is no Good Manufacturing Practice requirement. The third-party Certificate of Analysis that better retailers post is one snapshot of one batch from one lab. What ships in the envelope from month to month is whatever the manufacturer puts in it.

What we may start seeing

Several Mexican ibogaine clinics have publicly named 7-OH kratom as among the hardest new presenting addictions of 2026. New Path Ibogaine, in Mexico, has stated that 7-OH has overtaken fentanyl as their most common addiction case this year. Other clinics we have spoken with describe the same pattern.

What none of them describes, at least not in public-facing materials, is a specific medication-bridge protocol that incorporates SR17018. The compound is too new, too unstudied in humans, and too unsupported by FDA or any pharmacy infrastructure for a clinic to publicly attach its name to it in 2026. That does not mean it isn't being used quietly. It does mean that any clinic doing so is taking on the regulatory and clinical risk privately rather than declaring it in their literature.

This may change. If SR17018 continues to circulate through consumer channels and 7-OH dependence keeps growing as a presenting addiction, it would not be surprising to see one or more ibogaine clinics incorporate it into a supervised pre-treatment protocol over the next 12 to 18 months. The clinical logic is plausible on paper: a short-window, lower-respiratory-depression bridge from a high-potency mu-opioid agonist into the ibogaine session. The barriers are not pharmacological. They are regulatory, supply-chain, and reputational.

What this article is not arguing is that SR17018 should be incorporated into clinic protocols. That is a clinical decision that requires real human data, real sourcing accountability, and real outcome tracking, none of which exist yet. What it is arguing is that the demand pressure on this question is real and growing, and the answer is going to come from either rigorous trials catching up, or clinics quietly experimenting, or both. The marketing copy on a strawberry chewable is not the answer.

What's on the consumer shelf

The most prominent consumer brand selling SR17018 in 2026 is O.R. Reset. The product is a strawberry-flavored chewable tablet, sold in three-counts and six-counts, through the brand's direct-to-consumer website and through head-shop retailers including Burmans Health Shop.

According to the publicly disclosed formulation (the reseller, Burmans, provides more product detail than the manufacturer's own site), each tablet contains 50 mg of SR17018, plus GABA, L-Theanine, and 150 mg of L-Tyrosine. The first ingredient does the receptor work. The other three are over-the-counter calming and focus aminos.

What is most interesting is the gap between how the manufacturer markets the product and how the reseller does.

The manufacturer's site (orreset.com) makes explicit therapeutic claims. The product, it says, will "restore your tolerance to baseline in just 10 days." Each tablet "takes away cravings while reset your receptors." A graphic on the homepage lists the things O.R. Reset "prevents," including withdrawals, restless legs, sweating, sleep issues, and tolerance buildup. The product is described as "non habit forming."

The reseller's listing reads like someone has had a careful conversation with a lawyer. Burmans says, in a clearly visible "Important Information" section, that O.R. Reset "is not a cure or treatment," "does not claim to eliminate dependency, cravings, or withdrawal," "is not a prescription medication," and "is not intended to diagnose, treat, cure, or prevent any disease." Same product. Different lawyers, apparently.

The reseller is operating in a way that is consistent with how kratom and other functional-alkaloid products have been sold in the US: cautious disclaimers, third-party COAs, no specific medical claims. The manufacturer is operating in a way that, historically, draws FDA warning letters. Whether one arrives is a matter of when, not if.

The honest read

If you are reading this and you are currently using 7-OH and looking for a path out, here is what I would want you to know.

SR17018 is not a tested human medication. The science behind it is interesting. The animal data is encouraging. But the gap between "interesting biased agonist research" and "buy a strawberry chewable off the internet to bridge yourself through withdrawal" is enormous, and that gap is currently being filled by marketing copy rather than by clinical evidence.

If a clinic ever does integrate SR17018 into a supervised pre-treatment protocol with medical staff on site, that would be a different proposition from buying it unsupervised. Supervised use within a clinic context would mean dosing decisions made by someone who can adjust them, complications caught early, and the patient's pre-ibogaine trajectory managed by a team. None of that is true for someone who orders a three-pack online today.

If you are considering an ibogaine treatment and you are currently on 7-OH, the better path is to talk to the clinic you are evaluating about how they handle your specific case. Ask them what their pre-treatment protocol looks like. Ask them whether they use a buprenorphine or methadone bridge, or another approach. Ask them how long the prep window is. Ask them who prescribes and administers the bridge medication. If a clinic cannot describe its 7-OH protocol with specificity, that is a useful signal.

If you are considering buying O.R. Reset on your own, without medical supervision, before approaching a clinic, please do not. Not because the compound is necessarily dangerous (we do not have the data to know either way), but because the goal you are trying to reach (a state your body is ready to receive ibogaine in) is a clinical question, and using an unapproved compound to get there without a clinician involved trades one set of risks for another.

One last thing

The people taking O.R. Reset, by and large, are not naive. They are people who have spent the last several months or years on 7-OH kratom, watching their lives get smaller, trying to put together a plan to stop. They are reading the same things you are reading. They are taking the same Reddit threads seriously. They are buying a strawberry chewable because no one in the medical system has offered them anything better, and the strawberry chewable is at least trying to look like an answer.

That last part is the saddest part of the story. There is a real public health need here. 7-OH kratom is the most common new opioid-class addiction at multiple ibogaine clinics in 2026. The conventional medical system has been slow to catch up. Into that gap, an unregulated consumer product has arrived first.

A research compound from a Florida pharmacology lab is now a strawberry chewable on a head-shop shelf. That should not be the best option a person has.

If you are researching ibogaine treatment for yourself or a loved one and you are currently using 7-OH kratom, start with the Clinic Directory. Several of the clinics there describe how they handle kratom cases.